ETC 588
Alternative Names: ESP-24228; ETC-588; Large unilamellar vesicles; LUVLatest Information Update: 17 May 2007
At a glance
- Originator Inex Pharmaceuticals Corporation
- Developer Esperion Therapeutics
- Class Phospholipids
- Mechanism of Action Apolipoprotein A-I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute coronary syndromes; Atherosclerosis